胰腺癌术后辅助立体定向放疗(SPARTA 试验):一项进行中 II 期单中心前瞻性研究的期中安全性分析
SPARTA 是一项 2021 年启动的 II 期单中心前瞻性研究,计划入组 50 例具有高危特征的胰腺癌术后患者,放疗剂量为 40 Gy/5 次。本次期中安全性分析中位随访 16.5 个月,未观察到 ≥G3 毒性,最常见为恶心、乏力、腹痛和腹泻。结论认为辅助 SBRT 耐受性可接受,但需更长随访明确晚期毒性。
要点
- 50 例胰腺癌术后患者接受 40 Gy/5 次辅助 SBRT,未出现 ≥G3 毒性。
- 放疗期间最常见毒性为 G1 恶心(18%)和 G1 腹痛(12%)。
- 6 至 12 个月观察到 2 例 G2 吸收不良,需关注晚期毒性。
核心结论
- 在本系列中,胰腺癌术后辅助 SBRT 耐受性可接受,未观察到 ≥G3 毒性。
- 需要更长随访才能充分描述晚期毒性,最终结果有待确认 SBRT 的安全性和有效性。
研究设计与样本
- SPARTA 为进行中的 II 期单中心前瞻性研究,2021 年启动,本文为期中安全性分析。
- 计划入组 50 例,入组期 36 个月,随后随访 12 个月,总研究时长 4 年。
- 纳入标准为 pT1-T4 腺癌,伴或不伴切缘阳性,和/或淋巴结清扫中 N1。
- 化疗可在新辅助和辅助阶段给予,放疗剂量为 40 Gy 分 5 次。
- 毒性按 CTCAE v5.0 记录,主要终点为局部复发,次要终点包括无病生存、总生存、失败模式、急性和晚期毒性。
主要发现
- 本次初步分析纳入 50 例患者,分析时中位随访 16.5 个月(范围 3-35)。
- 23 例(46%)接受新辅助化疗,30 例(60%)接受辅助化疗。
- 无患者发生 ≥G3 毒性。
- SBRT 期间最常见毒性为恶心(G1 18%;G2 8%)、乏力(G1 10%)、腹痛(G1 12%;G2 2%)和腹泻(G1 6%;G2 2%)。
- 3 个月和 6 个月后腹痛(16%)和腹泻(12%)仍是最常见的 G1-G2 毒性;6 个月和 12 个月时观察到 2 例 G2 吸收不良;1 年时记录到 G2 腹痛(4%)和 G1 腹泻(4%)。
关键数值与推荐
- 放疗剂量为 40 Gy 分 5 次。
- 毒性分级采用 CTCAE v5.0。
- 主要终点为局部复发,次要终点为无病生存、总生存、失败模式、急性和晚期毒性。
临床怎么用
- 对于具有高危特征(pT1-T4、切缘阳性或 N1)的胰腺癌术后患者,辅助 SBRT 40 Gy/5 次可作为耐受性可接受的治疗选择。
- 治疗期间及随访中应关注恶心、乏力、腹痛、腹泻和吸收不良等 G1-G2 毒性。
- 需更长随访以评估晚期毒性,最终结果待报告。
局限性
- 本文为期中安全性分析,随访时间短(中位 16.5 个月),晚期毒性尚未充分表征。
- 单中心 II 期研究,样本量 50 例,最终安全性和有效性有待确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: This interim safety/toxicity analysis aims to assess toxicity of adjuvant stereotactic body radiation therapy (SBRT) after surgery of pancreatic cancer (PC) with high risk features across an ongoing prospective phase II trial, allowing better integration of chemotherapy and surgery. METHODS: The study started in 2021 and this paper represents an interim safety analysis. Enrollment will last 36 months, followed by 12 months of follow-up for a duration of 4 years and 50 patients. Inclusion criteria are: pT1-T4 adenocarcinoma with or without positive resection margin and/or N1 at lymphadenectomy. Chemotherapy can be administered in neoadjuvant and adjuvant setting. The primary endpoint is local relapse. The secondary endpoints are disease-free survival, overall survival, patterns of failure, acute and late toxicity. Radiation dose is 40 Gy in 5 fractions. Toxicities are recorded according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0. The study protocol was approved by the institutional research ethics committee on May 18th 2021 and registered on ClinicalTrials.gov (NCT05043857). RESULTS: This preliminary analysis was focused on 50 patients. The median follow-up at the time of the analyses was 16.5 months (range 3-35). Neoadjuvant chemotherapy was administered to 23 patients (46%) and 30 (60%) received adjuvant chemotherapy. No patients experienced ≥ G3 toxicity. The most frequent toxicities during SBRT were: nausea (G1, 18%; G2, 8%), asthenia (G1, 10%), abdominal pain (G1, 12%; G2, 2%) and diarrhea (G1, 6%; G2, 2%). After 3 and 6 months abdominal pain (16%) and diarrhea (12%) remained the most G1-G2 toxicities. At 6 and 12 months, we observed two cases of G2 malabsorption. At 1 year, we recorded G2 abdominal pain (4%) and G1 diarrhea (4%). CONCLUSIONS: In this series, adjuvant SBRT in PC was associated with acceptable tolerability with no ≥G3 toxicity. A longer follow-up is needed to fully characterize late toxicity. The final results are awaited to confirm the safety and efficacy of SBRT as a new therapeutic option for patients with resected PC. TRIAL REGISTRATION: The study protocol was approved by the institutional research ethics committee (Comitato Etico Indipendente IRCCS Humanitas Research Hospital) on May 18th 2021 and registered on ClinicalTrials.gov (NCT05043857) on September 14th 2021.
引用
- Massaro M, Comito T, Franzese C, et al. Adjuvant stereotactic pancreatic radiotherapy (SPARTA trial): interim safety analysis of an ongoing phase II single center prospective study. Radiat Oncol. 2026. PMID: 42129843. doi:10.1186/s13014-026-02848-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。